Company news

Imagion Biosystems Ltd. news in 2026

Imagion Biosystems Ltd.'s news releases, calls and decks from 2026, newest first.

View company

IBX Announces NED Resignation & Change of Company Secretary

October 29, 2026

Amended Appendix 4C - September 2026

October 26, 2026

Appendix 4C and Quarterly Activities Report - September 2026

October 7, 2026

IBX Secures Central Ethics Approval - Key Phase 2 Milestone

September 29, 2026

Imagion Resumes MagSense® Nanoparticle Manufacturing Capabilities

September 14, 2026

MagSense Nanoparticle Manufacturing Update

September 13, 2026

IBX Investor Presentation

September 3, 2026

Cleansing Notice

August 31, 2026

Application for quotation of securities - IBX

August 31, 2026

Application for quotation of securities - IBX

August 31, 2026

Notification of cessation of securities - IBX

August 26, 2026

IBX Phase 2 Clinical Trial Update

August 25, 2026

Change of Director's Interest Notices - RP, BM, NW

August 25, 2026

Appendix 4D and Half-yearly Financial Report

August 24, 2026

Cleansing Notice

August 17, 2026

Application for quotation of securities - IBX

August 17, 2026

Cleansing Notice

August 17, 2026

Application for quotation of securities - IBX

August 17, 2026

Results of General Meeting

August 9, 2026

Appendix 4C and Quarterly Activities Report - June 2026

July 30, 2026

Proposed issue of securities - IBX

July 28, 2026

Non-Dilutive Short-Term Funding Secured

July 28, 2026

Imagion Biosystems Secures AU$3.75M in Capital Raise Following FDA Clearance of Phase 2 Clinical Trial

June 25, 2026

IBX Secures Firm Commitments for $3.75m for Clinical Trial

June 24, 2026

Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review

June 2, 2026

Imagion Biosystems Receives IND Clearance from US FDA

June 1, 2026

Appendix 4C and Quarterly Activities Report - March 2026

April 23, 2026

FY25 Appendix 4E and Annual Report

February 27, 2026

Medical-imaging company Imagion Biosystems Lodges IND with FDA for Phase 2 Trial of MagSense® HER2 targeted imaging agent

February 3, 2026

IBX's IND Application Lodged with FDA for HER2 Phase 2 Trial

February 1, 2026

Appendix 4C and Quarterly Activities Report - December 2025

January 28, 2026

Mercer Convertible Securities Conversion and Amendment

January 7, 2026

Decks in 2026